Recent Advances in the Development of Protein-protein Interactions Modulators: Mechanisms and Clinical Trials

Overview

Journal Signal Transduct Target Ther

Specialties Cell Biology
Pharmacology

Date 2020 Sep 24

PMID 32968059

Citations 290

Authors

Haiying Lu

Qiaodan Zhou

Jun He

Zhongliang Jiang

Cheng Peng

Rongsheng Tong

Jianyou Shi

Affiliations

Soon will be listed here.

Abstract

Protein-protein interactions (PPIs) have pivotal roles in life processes. The studies showed that aberrant PPIs are associated with various diseases, including cancer, infectious diseases, and neurodegenerative diseases. Therefore, targeting PPIs is a direction in treating diseases and an essential strategy for the development of new drugs. In the past few decades, the modulation of PPIs has been recognized as one of the most challenging drug discovery tasks. In recent years, some PPIs modulators have entered clinical studies, some of which been approved for marketing, indicating that the modulators targeting PPIs have broad prospects. Here, we summarize the recent advances in PPIs modulators, including small molecules, peptides, and antibodies, hoping to provide some guidance to the design of novel drugs targeting PPIs in the future.

Citing Articles

Site-specific molecular glues for the 14-3-3/Tau pS214 protein-protein interaction reversible covalent imine tethering.

Oberheide A, van den Oetelaar M, Scheele J, Borggrafe J, Engelen S, Sattler M RSC Med Chem. 2025; .

PMID: 40070456 PMC: 11892739. DOI: 10.1039/d4md00833b.

Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines.

Xiao W, Jiang W, Chen Z, Huang Y, Mao J, Zheng W Signal Transduct Target Ther. 2025; 10(1):74.

PMID: 40038239 PMC: 11880366. DOI: 10.1038/s41392-024-02107-5.

Focal Molography Allows for Affinity and Concentration Measurements of Proteins in Complex Matrices with High Accuracy.

Dirscherl L, Merz L, Kobras R, Spies P, Frutiger A, Gatterdam V Biosensors (Basel). 2025; 15(2).

PMID: 39996969 PMC: 11853488. DOI: 10.3390/bios15020066.

Uncovering proteome variations and concomitant quality changes of different drying methods by 4D-DIA structural proteomics.

Xiao M, Tang C, Wang T, He M, Li Y, Li X Front Nutr. 2025; 12:1463780.

PMID: 39973924 PMC: 11835701. DOI: 10.3389/fnut.2025.1463780.

Multiple Chaperone DnaK-FliC Flagellin Interactions are Required for Pseudomonas aeruginosa Flagellum Assembly and Indicate a New Function for DnaK.

Molinari G, Ribeiro S, Muller K, Mayer B, Rohde M, Arce-Rodriguez A Microb Biotechnol. 2025; 18(2):e70096.

PMID: 39937155 PMC: 11816700. DOI: 10.1111/1751-7915.70096.

References

Zhang D . The Nrf2-Keap1-ARE signaling pathway: The regulation and dual function of Nrf2 in cancer. Antioxid Redox Signal. 2010; 13(11):1623-6. DOI: 10.1089/ars.2010.3301. View

Kuberappa P, Bagalad B, Ananthaneni A, Kiresur M, Srinivas G . Certainty of S100 from Physiology to Pathology. J Clin Diagn Res. 2016; 10(6):ZE10-5. PMC: 4963792. DOI: 10.7860/JCDR/2016/17949.8022. View

Socinski M, Jotte R, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N . Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018; 378(24):2288-2301. DOI: 10.1056/NEJMoa1716948. View

Heo J, Eki R, Abbas T . Deregulation of F-box proteins and its consequence on cancer development, progression and metastasis. Semin Cancer Biol. 2015; 36:33-51. PMC: 4761475. DOI: 10.1016/j.semcancer.2015.09.015. View

Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D . RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer. 2011; 11(11):761-74. PMC: 3632399. DOI: 10.1038/nrc3106. View

Gray Jr P, Prince T, Cheng J, Stevenson M, Calderwood S . Targeting the oncogene and kinome chaperone CDC37. Nat Rev Cancer. 2008; 8(7):491-5. PMC: 2779120. DOI: 10.1038/nrc2420. View

Holzer P, Masuya K, Furet P, Kallen J, Valat-Stachyra T, Ferretti S . Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors. J Med Chem. 2015; 58(16):6348-58. DOI: 10.1021/acs.jmedchem.5b00810. View

Chai J, Du C, Wu J, Kyin S, Wang X, Shi Y . Structural and biochemical basis of apoptotic activation by Smac/DIABLO. Nature. 2000; 406(6798):855-62. DOI: 10.1038/35022514. View

Ward G, Lewis E, Ahn J, Johnson C, Lyons J, Martins V . ASTX660, a Novel Non-peptidomimetic Antagonist of cIAP1/2 and XIAP, Potently Induces TNFα-Dependent Apoptosis in Cancer Cell Lines and Inhibits Tumor Growth. Mol Cancer Ther. 2018; 17(7):1381-1391. DOI: 10.1158/1535-7163.MCT-17-0848. View

10.

Zarzycka B, Kuenemann M, Miteva M, Nicolaes G, Vriend G, Sperandio O . Stabilization of protein-protein interaction complexes through small molecules. Drug Discov Today. 2015; 21(1):48-57. DOI: 10.1016/j.drudis.2015.09.011. View

11.

Jiang Z, Lu M, Xu L, Yang T, Xi M, Xu X . Discovery of potent Keap1-Nrf2 protein-protein interaction inhibitor based on molecular binding determinants analysis. J Med Chem. 2014; 57(6):2736-45. DOI: 10.1021/jm5000529. View

12.

Oltersdorf T, Elmore S, Shoemaker A, Armstrong R, Augeri D, Belli B . An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005; 435(7042):677-81. DOI: 10.1038/nature03579. View

13.

Antonia S, Villegas A, Daniel D, Vicente D, Murakami S, Hui R . Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 377(20):1919-1929. DOI: 10.1056/NEJMoa1709937. View

14.

Yin H, Lee G, Sedey K, Kutzki O, Park H, Orner B . Terphenyl-Based Bak BH3 alpha-helical proteomimetics as low-molecular-weight antagonists of Bcl-xL. J Am Chem Soc. 2005; 127(29):10191-6. DOI: 10.1021/ja050122x. View

15.

Ferris R, Blumenschein Jr G, Fayette J, Guigay J, Colevas A, Licitra L . Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016; 375(19):1856-1867. PMC: 5564292. DOI: 10.1056/NEJMoa1602252. View

16.

Chung C, Dean A, Woolven J, Bamborough P . Fragment-based discovery of bromodomain inhibitors part 1: inhibitor binding modes and implications for lead discovery. J Med Chem. 2011; 55(2):576-86. DOI: 10.1021/jm201320w. View

17.

Argiriadi M, Benatuil L, Dubrovska I, Egan D, Gao L, Greischar A . CD40/anti-CD40 antibody complexes which illustrate agonist and antagonist structural switches. BMC Mol Cell Biol. 2019; 20(1):29. PMC: 6683420. DOI: 10.1186/s12860-019-0213-4. View

18.

Perez de Vega M, Martin-Martinez M, Gonzalez-Muniz R . Modulation of protein-protein interactions by stabilizing/mimicking protein secondary structure elements. Curr Top Med Chem. 2007; 7(1):33-62. DOI: 10.2174/156802607779318325. View

19.

Gyrd-Hansen M, Meier P . IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat Rev Cancer. 2010; 10(8):561-74. DOI: 10.1038/nrc2889. View

20.

Chang Y, Graves B, Guerlavais V, Tovar C, Packman K, To K . Stapled α-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy. Proc Natl Acad Sci U S A. 2013; 110(36):E3445-54. PMC: 3767549. DOI: 10.1073/pnas.1303002110. View